Permeability Factor in Focal Segmental Glomerulosclerosis

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

December 31, 2000

Primary Completion Date

June 30, 2014

Study Completion Date

June 30, 2014

Conditions
Focal Segmental Glomerulosclerosis
Interventions
PROCEDURE

Plasma exchange

A course of plasma exchange of 5 treatments over 10 days, then administration of cyclophosphamide.

DRUG

Cyclophosphamide

For GFR \> 50 ml/min/1.73 m2 received oral cyclophosphamide at a dose of 2 mg/kg/ day for 3 months. For GFR \< 50 ml/min/1.73 m2 but \> 10 ml/min/1.73 m2 will receive oral cyclophosphamide at a 25% reduced dose or 1.5 mg/kg/d for 3 months.

Trial Locations (1)

20892

National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda

All Listed Sponsors
lead

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

NIH

NCT00007475 - Permeability Factor in Focal Segmental Glomerulosclerosis | Biotech Hunter | Biotech Hunter